APA

Schmeling H., Minden K., Foeldvari I., Ganser G., Hospach T. & Horneff G. (20141028). Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. : Arthritis & rheumatology (Hoboken, N.J.).

Chicago

Schmeling Heinrike, Minden Kirsten, Foeldvari Ivan, Ganser Gerd, Hospach Tony and Horneff Gerd. 20141028. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. : Arthritis & rheumatology (Hoboken, N.J.).

Harvard

Schmeling H., Minden K., Foeldvari I., Ganser G., Hospach T. and Horneff G. (20141028). Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. : Arthritis & rheumatology (Hoboken, N.J.).

MLA

Schmeling Heinrike, Minden Kirsten, Foeldvari Ivan, Ganser Gerd, Hospach Tony and Horneff Gerd. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry. : Arthritis & rheumatology (Hoboken, N.J.). 20141028.